Latest news with #AllenBond
Business Wire
6 days ago
- Business
- Business Wire
Jensen Quality Growth ETF Marks One-Year Anniversary with Steady Growth
LAKE OSWEGO, Ore.--(BUSINESS WIRE)--Jensen Investment Management ("Jensen") today commemorates the one-year anniversary of the Jensen Quality Growth ETF (JGRW), which launched in August 2024 to provide investors with additional access to the firm's well-established, high-conviction investment strategy. Built on more than 30 years of investment discipline, JGRW applies Jensen's time-tested investment philosophy, rooted in an unwavering commitment to investing in quality businesses. JGRW targets companies with a consistent 10-year history of 15 percent or greater return on equity, are in excellent financial condition, and capable of sustaining outstanding business performance, aiming to deliver long-term capital appreciation while mitigating downside risk. Since its inception, JGRW has grown to $69M in total net assets, as of 7/31/2025. The ETF is managed by the same Investment Team which oversees Jensen's full suite of quality-focused strategies. 'This milestone reflects our continued commitment to disciplined investing and making our strategy more accessible to a wider range of investors,' said Allen Bond, Managing Director and Portfolio Manager. 'JGRW delivers the same quality-focused, long-term approach that has defined our firm for decades, now in a structure that offers added liquidity and tax efficiency.' 'We launched JGRW to meet growing demand from advisors and investors looking for high-conviction strategies in a modern ETF wrapper,' said Richard Clark, Managing Director, Business Development at Jensen. 'We're proud of the progress over this first year and energized by the conversations we're having with new investors and platform partners.' For additional details and performance data, please visit: About Jensen Investment Management Founded in 1988, Jensen Investment Management is an independent, active equity manager with an unwavering commitment to quality. The firm invests exclusively in companies with a long-term record of consistently high returns on equity. Its approach is rooted in disciplined fundamental research, a focus on downside protection, and high-conviction portfolio construction. Jensen is based in Lake Oswego, Oregon. For more information, visit DISCLOSURES: The Jensen Quality Growth ETF is distributed by Foreside Fund Services, LLC. Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For prospectus or summary prospectus with this and other information about the Fund, please visit our website at Read the prospectus carefully before investing. Investing involves risk including the possible loss of principal. The market value of stocks held by the Fund may decline over a short, or even an extended period of time, resulting in a decrease in the value of a shareholder's investment. The Fund is non-diversified and is permitted to invest a greater portion of its assets in the securities of a smaller number of issuers than would be permissible if it were a 'diversified' fund and therefore, it may be more sensitive to market changes than a diversified fund. Larger, more established companies may be unable to respond quickly to new competitive challenges such as changes in consumer tastes or innovative smaller competitors. Also, large-cap companies are sometimes unable to attain the high growth rates of successful, smaller companies, especially during extended periods of economic expansion. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors have a limited track record on which to base their investment decision. ETFs are subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.
Yahoo
28-07-2025
- Business
- Yahoo
Healthcare stocks: Buy Stryker, pass on UnitedHealth
Jensen Investment Management managing director and portfolio manager Allen Bond joins Market Domination host Josh Lipton to discuss two healthcare stocks: Stryker (SYK), which Bond recommends buying, and UnitedHealth (UNH), which he suggests avoiding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Welcome to Goodbye or Goodbye. Our goal here is to help cut through that noise to navigate the best moves for your portfolio. I'm here with Jensen investment management managing, managing director and portfolio manager, that would be Alan Bond. Alan, is good to see you. Let's walk through some of the moves here, Alan. We're gonna start with one you like. Uh the buy here would be striker. Now, this one is up about 10% year to date. Most analysts on the street still like this one. They think it's a buy. I want to go through the reasons why you think it's a buy. Start here. Benefits from higher AC utilization. Yeah, this is pretty straightforward for striker. Striker is a leader in orthopedic implants and healthcare equipment. Uh so higher utilization of the healthcare system system means more utilization of implants, more utilization of healthcare tools. And benefit striker's volume. So they are a beneficiary of higher healthcare utilization and that's what we're seeing right now. Uh another reason you are telling people this one's a buy, taking market share. Yeah, and this is really important for striker. So the orthopedic implants implant space, um traditionally share does not change very much. There these are entrenched players, striker is one of the big ones. But striker has been taking share. Uh and the reason they've been taking share is really twofold. One is technology leadership. Um Striker was first to market with a robot assisted surgery platform for orthopedic procedures and that's allowed them to take share in otherwise areas where it's difficult to take share. The other is execution. Um more and more procedures are being done outside of the hospital and what's called ambulatory surgical centers. Striker's execution in that space has been superior and it's allowed them again to drive share, drive volumes. All right. Third reason you say it's a buy. Pricing is improving. Yeah. Um pricing is improving. So so traditionally uh orthopedic implants, there's always a little bit of ongoing pricing pressure. But it's improving for striker for two reasons. Number one, um their business mix is changing. So they're they're they've diversified outside of just orthopedic implants where pricing is better. Secondly, because of the strength of that robotic platform, they can get better price on the orthopedic implants. So overall we we we've shifted to a story where we get volume and a little bit of price. All right. So you made a compelling case, Alan. But before viewers, they all pile in. Let's talk about downside risk here to this name. What do you see? Yeah, so this you got to hear. Um this is a popular stock. Um a lot of what I've talked about has been going on for a long time. Striker has been executing at a high level for a long time. So we think it's sustainable. That's why it's a top holding for us. But the risk is if you have a shares that are trading at a bit of a premium and there's a slip up, you could see a negative reaction. Um again, we don't we don't expect that. We we we have confidence that can that they can continue to execute. All right. So that's your buy. Let's move on to a name you would avoid here. And that would be United Health. I want to go through these reasons. One reason you say to avoid, higher AC utilization hurts profit margins. Yeah, so it's it's the inverse for United Health. So United Health is a health insurance company. And simply speaking, higher utilizations means higher costs, which means lower profit margins. They get to keep less of the premiums that they earn. And that's been a big story. You showed the stock price graph, the stock declining. That's one of the big reasons why we've seen a spike in utilization, spike in care costs and therefore lower profitability for for United Health. All right. Second reason you would not commit capital, reimbursement is under pressure. Yeah, so so this this speaks to their business mix. And one of the things that's great about United Health is they're very diversified. Uh but they do serve um patients in Medicare and in Medicaid. Uh Medicare reimbursements been under pressure. They've changed some of the coding they do to reimburse. Uh and Medicaid we're expecting that as well. So reimbursement which is essentially for price for them is kind of the inverse of striker against striker. It's improving for them. Uh it's getting worse. And the third and final reason you say this one is one to avoid, high uncertainty. Yeah, that the uncertainty right now uh is is really high with this one. Um there's been a there is a abrupt management change at the senior level. Um they've withdrawn their financial guidance for the year. All they've indicated is that the the the first two items here, that the the healthcare utilization trends keep getting worse. Uh they're going to report earnings here in a couple weeks and it's going to be very interesting to see how this uh this updates as the year unfolds. Yeah, earnings called July 29th. What would be on the upside risk to your call here? Um well, the the we need to see stabilization. Right? And they they they pulled guidance, which is very unusual for this company that this is a company that gives guidance early. It's rock solid. They often increase it. So this was a big change for investors, but to the extent that they can reinstate it and create kind of a floor and expectations that's credible, um that that would be probably the start of the way back for them. And and the stock, Alan, has been shelled already. I mean, it's down about 40% this year, but you obviously look at that and say, listen, that that actually is not still pricing in all the bad news. Bad news is priced in. Uh what's really difficult right now is measuring that bad news because the financial results have been or the financial guidance has been withdrawn. And so now we're left to speculate. We kind of know the trends. It's a matter of like how how bad do those trends get before they get better. All right. So buy striker avoid United Health. Alan, thanks so much for your time today. Appreciate it. And thank you all for watching. Goodbye or Goodbye. Thank you. Related Videos PagerDuty reportedly explores sale, Coinbase, Lockheed Martin Tesla, Samsung, energy stocks, & European semiconductors climb Cheap stock trading is rising this year: What does it mean? Paramount, Disney, Warner Bros. Discovery: Media earnings preview Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
